The atypical neuroleptics iloperidone and lurasidone inhibit human cytochrome P450 enzymes in vitro. Evaluation of potential metabolic interactions.
CONCLUSION: The examined neuroleptics showed inhibitory effects on different CYP enzymes. The obtained results indicate that metabolic/pharmacokinetic interactions with iloperidone (involving mainly CYP3A4 and CYP2D6) and possibly with lurasidone (involving CYP1A2, CYP2C9 or CYP2C19) may occur during combined therapy.
PMID: 32279279 [PubMed - as supplied by publisher]
Source: Pharmacological Reports - Category: Drugs & Pharmacology Authors: Danek PJ, Wójcikowski J, Daniel WA Tags: Pharmacol Rep Source Type: research
More News: Brain | Caffeine | Diclofenac | Drugs & Pharmacology | Liver | Neurology | Study | Urology & Nephrology | Voltaren